Antipodean Pharmaceuticals Overview

  • Founded
  • 2002
Founded
  • Status
  • Private
  • Latest Deal Type
  • Undetermined

Antipodean Pharmaceuticals General Information

Description

Developer of mitochondria-targeted compounds for disorders associated with mitochondrial dysfunction and oxidative stress. The Company is developing a mitochondria-targeted antioxidant, MitoQ (mitoquinone mesylate), for the treatment of hepatic inflammatory disorders caused by oxidative stress such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • PO Box 776
  • Menlo Park, CA 94026
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Antipodean Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Undetermined 30-Sep-2009 000.00 Completed
2. Later Stage VC (Series A3) 13-Dec-2007 00.000 000.00 0000 Completed Product Development
1. Later Stage VC (Series A2) 26-Aug-2005 $14.6M $14.6M 000.00 Completed Product Development
To view Antipodean Pharmaceuticals’s complete valuation and funding history, request access »

Antipodean Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3 0,000,000 00.000000 00.00 00 00 00 00 0.000
Series A2 00,000,000 00.000000 00.00 00 00 00 00 00.000
Series A1 13,680,000 $0.001000 $0.05 $0.56 $0.56 1x $0.56 38%
Series A 50,000 $0.001000 $0.04 $0.5 $0.5 1x $0.5 0.14%
To view Antipodean Pharmaceuticals’s complete cap table history, request access »

Antipodean Pharmaceuticals Board Members (1)

Name Representing Role Since
Gary Lane Self Chairman 000 0000
To view Antipodean Pharmaceuticals’s complete board members history, request access »